Phenurone — Competitive Intelligence Brief

Phenurone (PHENACEMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

marketed Sodium channel protein type 1 subunit alpha Neuroscience Small molecule

Target snapshot

Phenurone (PHENACEMIDE) — Abbvie.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Phenurone TARGET	PHENACEMIDE	Abbvie	marketed		Sodium channel protein type 1 subunit alpha	1951-01-01
Carbocaine	MEPIVACAINE	Eastman Kodak	marketed	Amide Local Anesthetic	Sodium channel protein type 1 subunit alpha	1960-01-01
Keppra	Keppra	Masonic Cancer Center, University of Minnesota	marketed		Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A
Lamictal	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha
Ropivacain	Ropivacain	University Hospital, Basel, Switzerland	marketed		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Carbocaine	Carbocaine	Nantes University Hospital	marketed		Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha
Naropeine	Naropeine	University Hospital, Rouen	phase 3		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-01-07 — Lamictal · 8637512 · Formulation · US
• 2040-05-29 — Lamictal · 11596634 · Method of Use · US
• 2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape

No sponsor landscape data.